Status:
COMPLETED
Duration of Dual Anti-Platelet Therapy (DUAL-ACS)
Lead Sponsor:
University of Edinburgh
Collaborating Sponsors:
British Heart Foundation
Conditions:
Acute Coronary Syndrome
Coronary Artery Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Despite substantial evidence supporting the use of dual anti-platelet therapy in patients with acute coronary syndrome, there remains major uncertainty regarding the optimal duration of therapy. Recen...
Eligibility Criteria
Inclusion
- Aged ≥18 years
- Clinical diagnosis of Type 1 myocardial infarction within 12 weeks
- In the opinion of the attending clinician requires dual anti-platelet therapy with aspirin and a P2Y12 receptor antagonist
- Resident in the country of recruitment with their unique health identifier
- The attending clinician has equipoise regarding the duration of therapy
- Provision of informed consent
Exclusion
- Clear indication for specific duration of dual anti-platelet therapy
- Type 2 myocardial infarction
- Contraindication to aspirin or P2Y12 receptor antagonist
- Non-resident in the country of recruitment
- Previous recruitment into the trial
- Inability or unwilling to give informed consent
Key Trial Info
Start Date :
April 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 4 2023
Estimated Enrollment :
4576 Patients enrolled
Trial Details
Trial ID
NCT03252249
Start Date
April 26 2018
End Date
February 4 2023
Last Update
May 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Edinburgh Royal Infirmary
Edinburgh, United Kingdom